The founders of NormOxys are working to commercialize molecules similar to those that give migratory birds the fortitude to fly thousands of miles. When the compound inositol pentaphosphate binds to the protein hemoglobin, its presence helps release up to three of the four oxygen molecules that hemoglobin picks up in the lungs and carries out to the body. NormOxys is betting that its lead candidate can help elevate oxygen levels in human tissues that lack it, and so become a treatment for a range of disorders, from heart failure to diabetic retinopathy, traumatic blood loss, and even cancer.
16 Laurel Avenue
Suite 150
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.
Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.
Small-cell lung cancer treatment is rapidly evolving, but Jazz and Roche are set to create a new maintenance therapy setting with their Zepzelca plus Tecentriq combination.
All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.
The information flow in the months before the approval of GSK’s Nucala in COPD provides an interesting case study, and brings to mind the cautionary tale of Alnylam’s Onpattro.
The company highlighted the KLK2-targeting agent’s safety at ASCO but it may have to rely on combinations to make pasritamig competitive.
The drugmaker presented oral abstracts at the meeting for Libtayo in adjuvant cutaneous squamous-cell carcinoma and linvoseltamab in multiple myeloma.
